{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:36:51Z","timestamp":1771364211290,"version":"3.50.1"},"reference-count":14,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Omadacycline is a first-in-class aminomethylcycline antibiotic with microbiological activity against Gram-positive and Gram-negative aerobes and anaerobes and atypical bacteria that is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). The bioavailability of a phase 3 tablet formulation relative to that obtained via intravenous (i.v.) administration (and of other oral formulations relative to that of the phase 3 tablet) was investigated in an open-label, randomized, four-period, crossover study with healthy subjects age 18 to 50 years. Subjects received omadacycline at 100 mg i.v., 300 mg orally as two different tablet formulations with different dissolution profiles, and 300 mg as an oral solution. Plasma omadacycline concentrations were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS\/MS) method. Twenty of 24 subjects completed all treatment periods. The two tablet formulations produced equivalent total exposures. The phase 3 tablet produced an exposure equivalent to that of the 100-mg i.v. dose, with a geometric mean ratio (90% confidence intervals [CI]) for area under the concentration-time curve from 0 h to infinity [AUC\n            <jats:sub>\u221e<\/jats:sub>\n            ]) of 1.00 (0.93, 1.07). The absolute bioavailability of the tablets was approximately 34.5%. Intersubject variability was consistent among the oral formulations (\u223c20 to 25%). Single oral and i.v. doses of omadacycline were well tolerated; three subjects experienced mild adverse events (dizziness, nausea, and vomiting) that resolved without intervention. A 300-mg dose of the tablet formulation of omadacycline intended for use in phase 3 studies produced a total exposure equivalent to that of a 100-mg i.v. dose.\n          <\/jats:p>","DOI":"10.1128\/aac.01393-16","type":"journal-article","created":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T17:04:42Z","timestamp":1476205482000},"page":"7431-7435","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":48,"title":["Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects"],"prefix":"10.1128","volume":"60","author":[{"given":"Haiying","family":"Sun","sequence":"first","affiliation":[{"name":"Novartis Institute for Biomedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Ting","sequence":"additional","affiliation":[{"name":"Novartis Institute for Biomedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendra","family":"Machineni","sequence":"additional","affiliation":[{"name":"Novartis Healthcare, Ltd., Hyderabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Praestgaard","sequence":"additional","affiliation":[{"name":"Novartis Institute for Biomedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kuemmell","sequence":"additional","affiliation":[{"name":"Novartis Institute for Biomedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Stein","sequence":"additional","affiliation":[{"name":"Novartis Institute for Biomedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gangadhar","family":"Sunkara","sequence":"additional","affiliation":[{"name":"Novartis Institute for Biomedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Kovacs","sequence":"additional","affiliation":[{"name":"Novartis Institute for Biomedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Villano","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Ken","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Bhatia B Bowser T Chen J Ismail M McIntyre L Mechiche R Nelson M Ohemeng K Verma A Jones G Fallon M. 2003. PTK 0796 and other novel tetracycline derivatives exhibiting potent in vitro and in vivo activities against antibiotic resistant gram-positive bacteria poster F-755. Abstr 43rd Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_2_3_2","unstructured":"Biedenbach DJ Mendes RE Sader HS Jones RN. 2010. In vitro evaluation of PTK796 activity tested against Staphylococcus aureus including hospital- and community-associated MRSA strains from the USA and Europe abstr E-1569. Abstr 50th Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_2_4_2","volume-title":"Abstr 22nd Eur Congr Clin Microbiol Infect Dis","author":"Flamm RK","year":"2012","unstructured":"Flamm RK, Farrell DJ, Sader HS, Jones RN. 2012. Antimicrobial activity of PTK 0796 (omadacycline) and comparator agents against contemporary pathogens commonly associated with community acquired respiratory tract infections collected during 2011 from the European Union, abstr P-1449. Abstr 22nd Eur Congr Clin Microbiol Infect Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"e_1_3_2_7_2","unstructured":"Craig WA Andes D Odinecs A. 2006. In vivo pharmacodynamics of MK-2764\/PTK 0796 against various gram-positive and gram-negative bacteria in the thighs of neutropenic and normal mice abstr P-1875. Abstr 46th Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-12"},{"key":"e_1_3_2_9_2","unstructured":"Sun H Ting L Flarakos J Dole K Praestgaard J Kovacs SJ Stein DS Sunkara G Tanaka SK. 2012. Pharmacokinetics of [14C]-labelled omadacycline (PTK 0796) in healthy male subjects abstr A-1281. Abstr 52nd Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_2_10_2","unstructured":"Ting L Sun H Kovacs SJ Klausner K Tanaka SK. 2010. Pharmacokinetics of intravenous and oral PTK796 a new aminomethylcycline antibiotic abstr K-124. Abstr 50th Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"},{"key":"e_1_3_2_12_2","first-page":"347","article-title":"Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects","volume":"57","author":"Gschwend MH","year":"2007","unstructured":"Gschwend MH, Martin W, Erenmemi\u015fo\u011flu A, Scherm M, Dilger C, Tamur U, Kanzik I, Hincal AA. 2007. Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. Arzneimittelforschung 57:347\u2013351.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_2_13_2","first-page":"532","article-title":"Bioequivalence study of two minocycline capsule formulations in healthy volunteers","volume":"59","author":"Setiawati E","year":"2009","unstructured":"Setiawati E, Purnomo A, Deniati SH, Yunaidi DA, Handayani LR, Harinato G, Santoso ID. 2009. Bioequivalence study of two minocycline capsule formulations in healthy volunteers. Arzneimittelforschung 59:532\u2013536.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_2_14_2","unstructured":"Leighton A Zupanets I Bezugla N Plamondon L Macdonald G Sutcliffe JA. 2011. Broad-spectrum fluorocycline TP-434 has oral bioavailability in human abstr P-1509. Abstr 21st Eur Congr Clin Microbiol Infect Dis."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00320-16"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01393-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01393-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:27:17Z","timestamp":1645475237000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01393-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1128\/AAC.01393-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.01393-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"2016-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}